Diarrhea chemotherapy-induced

Unlabeled Uses Control of bleeding esophageal varices, treatment of AIDS-associated secretory diarrhea, chemotherapy-induced diarrhea, insulinomas, small-bowel fistulas, control of bleeding esophageal varices... 

Arnold RJ, Gabrail N, Raut M, Kim R, Sung JC, Zhou Y. Clinical implications of chemotherapy-induced diarrhea in patients with cancer. J Support Oncol 2005 3(3) 227-32. 

Kobayashi K. [Chemotherapy-induced diarrhea.) Gan To Kagaku Ryoho 2003 30(6) 765-71. 

Richardson, G. and Dobish, R. 2007. Chemotherapy induced diarrhea. J Oncol Pharm Pract, 12 181-198. 

Viele, C.S. 2003. Overview of chemotherapy-induced diarrhea. Semin Oncol Nurs, 19(Supp 3) 2—5. 

Recombinant human IL-11 (oprelvekin) is a polypeptide of 177 amino acids. It differs from natural IL-11 due to lack of glycosylation and the amino-terminal proline residue. Oprelvekin is administered by subcutaneous injection, usually 6-24 h after chemotherapy, at a dose of 25-50 p,g/kg per day. The drug has a half-life of about 7h. It is used to stimulate bone marrow to induce platelet production in nonmyeloid malignancies in patients undergoing chemotherapy. The common side effects of oprelvekin include fluid retention, tachycardia, edema, nausea, vomiting, diarrhea, shortness of breath and mouth sores. Other side effects include rash at the injection site, blurred vision, paresthesias, headache, fever, cough and bone pain. Rarely, CLS may occur. 

Nervous system Methotrexate-induced myelopathy occurred in a woman with breast cancer and meningeal carcinomatosis, who was treated with intrathecal chemotherapy with methotrexate 15 mg and dexamethasone [70 ]. Five days after the last cycle, she developed bloody diarrhea, vomiting, urinary retention, and pancytopenia. While she recovered, progressive neurological deficits emerged. High doses of the key metabolites of the methyl-transfer pathway (adenosylmethio-nine, folinate, cyanocobalamin, and methionine) were substituted, after which the tetraparesis improved markedly. 

III trial, the associated death rate was 5%, predominantly in elderly patients with concomitant leukopenia and bacteremia [87 ]. Among patients with colorectal cancer, the presence of the primary tumor and previous episodes of chemotherapy-related diarrhea are susceptibility factors for fluorouracil-associated diarrhea [88 ]. Algorithms have been proposed for assessing and managing treatment-induced diarrhea [70 ]. 

---